Trial · NCT03540095
Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain
NCT03540095, Not applicable, Terminated, University of Pittsburgh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain. Trials, record NCT03540095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03540095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain
- NCT number
- NCT03540095
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Rib Fractures, Pain, Acute, Thoracic Injuries, Neuropathic Pain, Neuromuscular Blockade, Anesthesia, Local
- Interventions
- Erector Spinae Plane Block, Paravertebral Nerve Block
- First posted
- 2018-05-30
- Last updated
- 2019-05-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Opioid Consumption | first 72 hours after intervention | |
| Secondary | Visual Analog Scale (VAS) Pain Scores | Immediately prior to intervention. 15 minutes after intervention. 60 minutes after intervention. Daily (in morning) for 3 total days after intervention. | Visual Analog Scale is numerical from 0-10, with 10 being the worst pain imaginable, and 0 being no pain. The pain score will be recorded at rest and with deep breathing at the time intervals below. There are no subscales involved in this measurement. Simply, we will record single pain scores by VAS scale at rest and with deep breathing at indicated times. |
| Secondary | Adverse Events | During the expected duration of this study, which is on average 5 days. | We will record total number of pneumothoraxes, site infections, significant bleeding events, and unintentional catheter removals. Each of these events will be added separately per patient. We will analyze how many patients experience any adverse effect, and then further study the incidence of each specific adverse effect and compare them across both interventions. |
| Secondary | Number of Nerve Blocks | During the expected duration of this study, which is on average 5 days. | The provider will use his/her judgement to determine how many nerve blocks are required for management of the rib fracture pain. Compare the number of nerve blocks required for each type of intervention in the separate arms. |
| Secondary | Length of Stay | Will evaluate length of stay upon termination of the last study subject. Expected to be within 6 months of initiation of the trial. | Total length of hospitalization |
| Secondary | Time until discharge | Will evaluate length of stay upon termination of the last study subject. Expected to be within 6 months of initiation of the trial. | Time from intervention to discharge from hospital |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03540095
GET https://conductscience.org/api/trials/v1/NCT03540095/registered